MarketMoodz
Novo Nordisk sued over alleged scheme to delay Victoza generics for Ozempic
A class-action filed in the Eastern District of New York accuses Novo Nordisk A/S of unlawfully extending its Victoza monopoly through a multi-year anticompetitive scheme to delay generic Victoza. Plaintiffs claim the strategy preserved billions in profits by shifting patients to Ozempic before generics could enter.
Key Takeaways
- Plaintiffs allege the scheme delayed generic Victoza entry by at least 16 months
- The 2019 Teva settlement allegedly included a reverse payment and 180-day exclusivity for Teva's Victoza entry
- The complaint cites Hatch-Waxman-era patent listings in the FDA Orange Book as the regulatory mechanism for the delays
- Ozempic's market position is cited as central to the alleged shifts in prescriptions
- Market reaction showed Novo Nordisk stock down 0.87% to $58.82 at publication
People Involved
- JM Smith Corporation (d/b/a Smith Drug Company)Plaintiff
- Novo Nordisk A/SDefendant; Global pharmaceutical company
- Teva Pharmaceutical Industries Ltd.Co-defendant; generic-drug maker
Entities Involved
- Novo Nordisk A/S (NVO)Global pharmaceutical company; Victoza and Ozempic maker
- Teva Pharmaceutical Industries Ltd. (TEVA)Generic-drug manufacturer involved in Victoza competition
- JM Smith Corporation (d/b/a Smith Drug Company)Plaintiff in the EDNY lawsuit
- OzempicGLP-1 drug indicated for glycemic control and CV/kidney risk reduction
- VictozaLiraglutide injection for glycemic control; CV risk reduction
MarketMoodz Analysis
From an investor's lens, a ruling against Novo Nordisk could trigger penalties, settlements, or disgorgement that erode Victoza's monopoly and potentially dent Ozempic's pricing power. Any damages or settlements could undermine Novo Nordisk's revenue base tied to Victoza and the broader GLP-1 franchise.
Hatch-Waxman-era patent listings and settlements have drawn antitrust attention for decades; this case echoes earlier disputes around Teva's Victoza entry and a 2019 settlement that allegedly included a reverse payment and 180-day exclusivity window. The outcome could set a precedent for how regulators and courts view patent-based settlements in high-value diabetes drugs.
Monitor the EDNY docket and primary sources (the complaint, patent listings in the Orange Book, and any settlement terms) for material developments. A decision could influence Victoza's revenue base, Ozempic's pricing power, and broader incentives for generics in high-value biologic-like therapies.
Source: Original Article
Get AI-Powered Market Insights
Stay ahead of market-moving events with our real-time analysis and stock ratings.
Start Your Free Trial